2017 News Releases

Keyword Search
 
DateTitle  
11/09/17Dermira to Present at Upcoming Investor Conferences in November
MENLO PARK, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will present an overview of the company at two investor conferences in November. Stifel 2017 Healthcare Conference Location: New York, NY Presentation date... 
 Printer Friendly Version
11/06/17Dermira Reports Third Quarter 2017 Financial Results and Announces that FDA Accepts New Drug Application for Glycopyrronium Tosylate for the Treatment of Patients with Primary Axillary Hyperhidrosis
- FDA decision on New Drug Application expected by June 30, 2018 - Licensed exclusive, worldwide rights to lebrikizumab from Roche - Completed patient enrollment in two Phase 3 trials for the treatment of acne vulgaris - Agreed to end collaboration agreement with UCB for CIMZIA MENLO PARK, Calif., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new ther... 
 Printer Friendly Version
11/06/17Dermira and UCB Agree to End Collaboration Agreement for CIMZIA
Dermira to transition development and commercialization responsibility for CIMZIA® (certolizumab pegol) in psoriasis back to UCB Decision reflects both companies’ strategic priorities UCB remains committed to bringing CIMZIA to psoriasis patients upon regulatory approval Dermira to hold conference call at 1:30 p.m. PT/4:30 p.m. ET today MENLO PARK, Calif. and BRUSSELS, Belgium, Nov. 06, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) and UCB (Euronext:UCB) today announced the ... 
 Printer Friendly Version
10/13/17Dermira Highlights New Long-Term Safety Data for Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis at Fall Clinical Dermatology Conference
- Daily treatment with glycopyrronium tosylate in the Phase 3, open-label ARIDO trial was generally well-tolerated during 44 weeks of treatment - Efficacy assessment suggests sweat reduction levels were maintained in patients treated with glycopyrronium tosylate during the extended study MENLO PARK, Calif., Oct. 13, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, ne... 
 Printer Friendly Version
10/05/17Dermira Completes Patient Enrollment in Two Phase 3 Pivotal Trials of Olumacostat Glasaretil for the Treatment of Acne Vulgaris
- Phase 3 pivotal trials enrolled a total of 1,503 patients - Topline efficacy and safety results expected in first quarter of 2018 MENLO PARK, Calif., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced the completion of patient enrollment in its CLAREOS-1 and CLAREOS... 
 Printer Friendly Version
09/20/17Dermira to Present at Cantor Fitzgerald Global Healthcare Conference
MENLO PARK, Calif., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that it will present at the Cantor Fitzgerald 2017 Global Healthcare Conference. Andrew Guggenhime, chief operating officer and chief financial officer of Dermira, is scheduled to present at 8:00 a.... 
 Printer Friendly Version
09/14/17Dermira Announces Early Termination of the Hart-Scott-Rodino Waiting Period for License to Lebrikizumab
MENLO PARK, Calif., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that it has received early termination of the waiting period required by the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), related to its license to lebrikizumab.  The e... 
 Printer Friendly Version
09/14/17New CIMZIA® (certolizumab pegol) Findings Presented at European Academy of Dermatology and Venereology (EADV) Congress
Presentations included the first 48-week data from the CIMPASI-1 and CIMPASI-2 psoriasis trials, and re-randomized data through 48 weeks from the CIMPACT psoriasis trial 1,2 Treatment with CIMZIA was associated with significant and clinically meaningful improvements in quality of life and work productivity 3,4 No new safety signals were observed in the psoriasis trials and the safety profile remains consistent with CIMZIA’s other indications Additional presentations highlighted findings... 
 Printer Friendly Version
09/13/17Dermira Presents New Data Showing Impact of Primary Axillary Hyperhidrosis on Patients
People suffering from primary axillary hyperhidrosis (excessive underarm sweating beyond what is needed to maintain normal body temperature) report that the condition has a significant impact on their daily lives, often resulting in avoidance of social interactions and taking additional measures to manage their excessive sweating  Patients treated with glycopyrronium tosylate in Phase 3 clinical trials reported greater improvements across several measures designed to evaluate the impact of th... 
 Printer Friendly Version
09/07/17Dermira Presents New Data on Late-Stage Programs at Leading European Dermatology Congress
New findings from the glycopyrronium tosylate Phase 3 program highlight potential benefits of the investigational treatment and the impact of primary axillary hyperhidrosis on patients’ daily activities In collaboration with UCB, new 48-week data and quality of life findings from three clinical trials evaluating CIMZIA® (certolizumab pegol) in patients with moderate-to-severe chronic plaque psoriasis will also be presented MENLO PARK, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Dermira,... 
 Printer Friendly Version
08/08/17Dermira Enters into Agreement to License Exclusive, Worldwide Rights to Lebrikizumab
-  Dermira plans to develop and commercialize lebrikizumab, a monoclonal antibody targeting IL-13, for moderate-to-severe atopic dermatitis -  Initiation of a Phase 2b clinical study is expected in the first quarter of 2018 -  Management will host webcast and conference call today at 5:30 a.m. PT / 8:30 a.m. ET MENLO PARK, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by de... 
 Printer Friendly Version
08/07/17Dermira Reports Second Quarter 2017 Financial Results and Provides Corporate Update 
sBLA for CIMZIA® (certolizumab pegol) submitted to FDA Submission of NDA for glycopyrronium tosylate on schedule for second half of 2017 Guidance for Phase 3 olumacostat glasaretil topline results updated to first quarter of 2018 MENLO PARK, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with c... 
 Printer Friendly Version
07/25/17UCB and Dermira Announce U.S. and EU Regulatory Submissions for CIMZIA® (certolizumab pegol) for the treatment of Moderate-to-Severe Chronic Plaque Psoriasis
The regulatory submissions for this new indication seek to expand the use of CIMZIA for the treatment of patients with moderate-to-severe chronic plaque psoriasis Data from three positive Phase 3 studies support the regulatory submissions BRUSSELS, Belgium and MENLO PARK, Calif., July 25, 2017 (GLOBE NEWSWIRE) -- UCB (Euronext:UCB) and Dermira, Inc. (NASDAQ:DERM) today announced the UCB submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administ... 
 Printer Friendly Version
06/26/17Newly Published Nonclinical Data Highlight the Role of Olumacostat Glasaretil in Sebum Inhibition
MENLO PARK, Calif., June 26, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that findings from nonclinical studies evaluating the mechanism of action for olumacostat glasaretil (formerly DRM01) in sebum inhibition were published in the Journal of Investigative Dermatology (J... 
 Printer Friendly Version
06/06/17Dermira Announces Appointment of Ian Clements as Vice President, Investor Relations
MENLO PARK, Calif., June 06, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, announced today the addition of Ian Clements, Ph.D., to the company's leadership team as vice president, investor relations. Dr. Clements brings over 20 years of industry experience to Dermira. Most recently, he ... 
 Printer Friendly Version
05/30/17Dermira to Present at Jefferies 2017 Global Healthcare Conference
MENLO PARK, Calif., May 30, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that it will present at the Jefferies 2017 Global Healthcare Conference. Andrew Guggenhime, chief operating officer and chief financial officer of Dermira, is scheduled to present at 11:00 a.m. ET (8:... 
 Printer Friendly Version
05/16/17Dermira Announces Closing of 3.00% Convertible Senior Notes Offering
MENLO PARK, Calif., May 16, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today the closing of its previously announced offering of 3.00% Convertible Senior Notes due 2022 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Dermira issued $287.5 million aggregate principal amount of notes, including $37.5 million aggregate principal amount of notes issued pursuant to t... 
 Printer Friendly Version
05/10/17Dermira Prices Offering of $250 Million of 3.00% Convertible Senior Notes
MENLO PARK, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today the pricing of its offering of $250,000,000 aggregate principal amount of 3.00% Convertible Senior Notes due 2022 (the “notes”) in a private offering to qualified institutional buyers pursuant to the Securities Act of 1933, as amended (the “Securities Act”). Dermira also granted the initial purchasers of the notes a 30-day over-allotment option to purchase up to an additional $37,500,000 aggregate ... 
 Printer Friendly Version
05/09/17Dermira Announces Proposed Offering of $250 Million of Convertible Senior Notes
MENLO PARK, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today that it intends to offer, subject to market conditions and other factors, $250,000,000 aggregate principal amount of Convertible Senior Notes due 2022 (the “notes”) in a private offering to qualified institutional buyers pursuant to the Securities Act of 1933, as amended (the “Securities Act”). Dermira also intends to grant the initial purchasers of the notes a 30-day over-allotment option to purch... 
 Printer Friendly Version
05/08/17Dermira Reports First Quarter 2017 Financial Results and Provides Corporate Update 
-Submissions for CIMZIA® (certolizumab pegol) and glycopyrronium tosylate remain on schedule for later this year MENLO PARK, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today reported financial results for the quarter ended March 31, 2017 and provided an update on its cl... 
 Printer Friendly Version
03/28/17Dermira to Present at Needham 16th Annual Healthcare Conference
MENLO PARK, Calif., March 28, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that it will present at the Needham & Company 16th Annual Healthcare Conference. Andrew Guggenhime, chief operating officer and chief financial officer of Dermira, is scheduled to present at 2:2... 
 Printer Friendly Version
03/21/17Dermira Presents New Data Highlighting Patient Outcomes in Axillary Hyperhidrosis at Maui Derm Meeting
Proprietary Axillary Sweating Daily Diary patient-reported outcome instrument developed with feedback from FDA MENLO PARK, Calif., March 21, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today presented new information about the Axillary Sweating Daily Diary (ASDD), a proprietary patient-... 
 Printer Friendly Version
03/17/17Dermira to Highlight Data for Three Clinical Programs at Annual Maui Derm Meeting
New data for the Axillary Sweating Daily Diary patient-reported outcome instrument from the glycopyrronium tosylate Phase 2 trial in primary axillary hyperhidrosis to be highlighted Additional data from the CIMPACT Phase 3 trial of CIMZIA® (certolizumab pegol) in patients with moderate-to-severe psoriasis will be presented MENLO PARK, Calif., March 17, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical der... 
 Printer Friendly Version
03/07/17Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
MENLO PARK, Calif., March 07, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that it has closed its previously announced public offering of 5,750,000 shares of its common stock, including 750,000 shares sold upon full exercise of the underwriters’ option to purchase addition... 
 Printer Friendly Version
03/04/17New CIMZIA® (certolizumab pegol) data in moderate-to-severe plaque psoriasis and psoriatic arthritis presented at American Academy of Dermatology 2017 Annual Meeting
Late-breaking, investigational 16-week data presented from the CIMPASI-1 and CIMPASI-2 trials showing CIMZIA demonstrated statistically and clinically significant improvements for patients with moderate-to-severe chronic plaque psoriasis Four-year data from the CIMZIA RAPID-PSA study showing long-term maintenance of improvement in the joint and skin manifestations of psoriatic arthritis regardless of prior exposure to an anti-TNF, or as monotherapy without concomitant use of disease modifyi... 
 Printer Friendly Version
03/03/17Dermira Presents New Data in Primary Axillary Hyperhidrosis and Acne at American Academy of Dermatology 2017 Annual Meeting
Data from glycopyrronium tosylate Phase 3 program and olumacostat glasaretil Phase 2 trial show patients experienced early and sustained clinical effects with each treatment ORLANDO, Fla., March 03, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced new data, from its glycopyrr... 
 Printer Friendly Version
03/02/17Dermira to Present at Cowen and Company 37th Annual Health Care Conference
MENLO PARK, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that it will present at the Cowen and Company 37th Annual Health Care Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 4:00 p.m. ET (1:00 p.m. PT)... 
 Printer Friendly Version
03/01/17Dermira Prices $168.5 Million Public Offering of Common Stock
MENLO PARK, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced the pricing of its underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $33.70 per share. The gross proceeds to Dermira from the offering, before deductin... 
 Printer Friendly Version
02/28/17Dermira Announces Proposed Public Offering of Common Stock
MENLO PARK, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that it intends to offer 3,700,000 shares of its common stock in an underwritten public offering. Dermira also expects to grant to the underwriters a 30-day option to purchase up to 555,000 additiona... 
 Printer Friendly Version
02/28/17Dermira Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
-- Planned submission of NDA for glycopyrronium tosylate (formerly DRM04) in 2H17 on schedule after pre-NDA meeting with FDA -- -- Management to host webcast and conference call today 4:30 p.m. ET / 1:30 p.m. PT -- MENLO PARK, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions... 
 Printer Friendly Version
02/27/17Dermira Data from DRM04 and Olumacostat Glasaretil Clinical Programs to Be Presented at American Academy of Dermatology Annual Meeting
MENLO PARK, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that data from its DRM04 and olumacostat glasaretil (formerly DRM01) clinical programs will be presented during poster sessions at the 75th Annual Meeting of the American Academy of Dermatology (AAD) being held in Or... 
 Printer Friendly Version
02/22/17Dermira to Report Fourth Quarter and Full Year 2016 Financial Results
Management to Host Webcast and Conference Call on February 28, 2017 at 4:30 p.m. ET MENLO PARK, Calif., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it will report fourth quarter and full year 2016 financial results after the close of U.S. financial markets on February 28, 2... 
 Printer Friendly Version
02/08/17Dermira to Present at Leerink Partners 6th Annual Global Healthcare Conference
MENLO PARK, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. DERM, a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it will present at the Leerink Partners 6th Annual Global Healthcare Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 1:30 p.m. ET (10:30 a.m. PT) on Wednesday, February ... 
 Printer Friendly Version
01/19/17Final CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Primary Efficacy Endpoint in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
CIMPACT results confirm data from two previously reported Phase 3 CIMZIA trials Submission of marketing applications to regulatory authorities expected in third quarter of 2017 BRUSSELS, Belgium and MENLO PARK, Calif., Jan. 19, 2017 (GLOBE NEWSWIRE) -- UCB (Euronext:UCB) and Dermira, Inc. (NASDAQ:DERM) today announced key results from CIMPACT, a Phase 3, multi-center, placebo-controlled and active-controlled clinical trial evaluating the efficacy and safety of CIMZIA® (certolizumab pe... 
 Printer Friendly Version
01/06/17Dermira Provides Corporate Update
Treatment period for DRM04 ARIDO trial completed Phase 3 acne clinical program for olumacostat glasaretil initiated Topline data for third and final CIMZIA® (certolizumab pegol) Phase 3 trial expected first quarter of 2017 Chief Commercial Officer appointed MENLO PARK, Calif., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of... 
 Printer Friendly Version
01/05/17Lori Lyons-Williams Joins Dermira as Chief Commercial Officer
Previously served at Allergan as a Vice President for Sales & Marketing, member of Operational Leadership Team Worked on several leading dermatology brands including ACZONE® and BOTOX® during 15-year career at Allergan MENLO PARK, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, t... 
 Printer Friendly Version
01/04/17Dermira Elects Emmanuel Caeymaex to Board of Directors
Currently Executive Vice President, Immunology Patient Value Unit Head at UCB S.A. MENLO PARK, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced the election of Emmanuel Caeymaex, Executive Vice President, Immunology Patient Value Unit Head at UCB S.A., to its board of directo... 
 Printer Friendly Version
01/03/17Dermira Initiates Phase 3 Clinical Program in Acne
First patients dosed in Phase 3 program evaluating olumacostat glasaretil, a novel topical molecule, in patients with acne vulgaris Two Phase 3 trials expected to enroll a total of 1,400 patients Topline results expected in the first half of 2018 MENLO PARK, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with... 
 Printer Friendly Version